京津冀医药企业采暖季须错峰生产

2017-11-11 刘志勇 健康报

近日,工信部、环保部、国家卫生计生委、国家食药监管总局4部门联合发出《关于做好京津冀及周边地区医药企业采暖季错峰生产的通知》,要求北京、天津、河北、山东等省(市)相关部门如期完成京津冀及周边地区医药企业采暖季错峰生产工作任务,推进空气质量持续改进,保障药品有效供应。

近日,工信部、环保部、国家卫生计生委、国家食药监管总局4部门联合发出《关于做好京津冀及周边地区医药企业采暖季错峰生产的通知》,要求北京、天津、河北、山东等省(市)相关部门如期完成京津冀及周边地区医药企业采暖季错峰生产工作任务,推进空气质量持续改进,保障药品有效供应。

《通知》指出,各地要建立工作协调机制,研究制订医药企业采暖季错峰生产工作方案;严格落实属地责任,指导京津冀及周边地区“2+26”城市细化工作流程,明确责任分工,组织开展原料药生产企业排查,建立采暖季错峰生产企业和品种清单;相关信息材料及时报省级短缺药品供应保障工作会商联动机制。

京津冀及周边地区“2+26”城市医药企业涉及原料药生产的挥发性有机物排放工序,在采暖季原则上实施停产;由于民生等需求存在特殊情况确需生产的,应报省级政府批准。

各地要督促企业结合原料药生产工艺和技术特点,制定原料药采暖季错峰生产具体措施,明确停产品种、停产时限、停产方式等内容,严格按照要求实施停产。

《通知》要求,各地卫生计生部门要充分发挥省级短缺药品供应保障工作会商联动机制的作用,综合考虑短缺药品监测结果、国家基本药物品种、急(抢)救药品以及其他临床必需易短缺药品等方面因素,对按规定原则上应实施错峰生产的原料药品种,提出供应保障的建议。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1659898, encodeId=b18016598986d, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Mon Jun 18 02:58:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935722, encodeId=8a511935e2221, content=<a href='/topic/show?id=cda0352e61c' target=_blank style='color:#2F92EE;'>#医药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35276, encryptionId=cda0352e61c, topicName=医药企业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu Jan 18 23:58:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409169, encodeId=a922140916945, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Nov 13 02:58:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456133, encodeId=edbc14561330d, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Mon Nov 13 02:58:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517738, encodeId=f69d151e7380a, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Mon Nov 13 02:58:00 CST 2017, time=2017-11-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1659898, encodeId=b18016598986d, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Mon Jun 18 02:58:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935722, encodeId=8a511935e2221, content=<a href='/topic/show?id=cda0352e61c' target=_blank style='color:#2F92EE;'>#医药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35276, encryptionId=cda0352e61c, topicName=医药企业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu Jan 18 23:58:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409169, encodeId=a922140916945, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Nov 13 02:58:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456133, encodeId=edbc14561330d, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Mon Nov 13 02:58:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517738, encodeId=f69d151e7380a, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Mon Nov 13 02:58:00 CST 2017, time=2017-11-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1659898, encodeId=b18016598986d, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Mon Jun 18 02:58:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935722, encodeId=8a511935e2221, content=<a href='/topic/show?id=cda0352e61c' target=_blank style='color:#2F92EE;'>#医药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35276, encryptionId=cda0352e61c, topicName=医药企业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu Jan 18 23:58:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409169, encodeId=a922140916945, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Nov 13 02:58:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456133, encodeId=edbc14561330d, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Mon Nov 13 02:58:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517738, encodeId=f69d151e7380a, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Mon Nov 13 02:58:00 CST 2017, time=2017-11-13, status=1, ipAttribution=)]
    2017-11-13 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=1659898, encodeId=b18016598986d, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Mon Jun 18 02:58:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935722, encodeId=8a511935e2221, content=<a href='/topic/show?id=cda0352e61c' target=_blank style='color:#2F92EE;'>#医药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35276, encryptionId=cda0352e61c, topicName=医药企业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu Jan 18 23:58:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409169, encodeId=a922140916945, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Nov 13 02:58:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456133, encodeId=edbc14561330d, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Mon Nov 13 02:58:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517738, encodeId=f69d151e7380a, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Mon Nov 13 02:58:00 CST 2017, time=2017-11-13, status=1, ipAttribution=)]
    2017-11-13 hyf030
  5. [GetPortalCommentsPageByObjectIdResponse(id=1659898, encodeId=b18016598986d, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Mon Jun 18 02:58:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935722, encodeId=8a511935e2221, content=<a href='/topic/show?id=cda0352e61c' target=_blank style='color:#2F92EE;'>#医药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35276, encryptionId=cda0352e61c, topicName=医药企业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu Jan 18 23:58:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409169, encodeId=a922140916945, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Nov 13 02:58:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456133, encodeId=edbc14561330d, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Mon Nov 13 02:58:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517738, encodeId=f69d151e7380a, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Mon Nov 13 02:58:00 CST 2017, time=2017-11-13, status=1, ipAttribution=)]

相关资讯

上半年“京医”河北接诊患者破万 京津冀医学检验结果互认将扩大

包括北京儿童医院、北京口腔医院在内的五大北京市属医院与河北保定五家医院结对子,助力该地区医疗发展。同时,京津冀将在扩大三地医学检验结果互认、医学影像资料共享、卫生应急、药品医用耗材集中采购等领域继续开展合作。8月25日上午,北京市卫生计生委、河北省卫生计生委和保定市政府共同签订《医疗卫生协同发展框架协议》,北京市5家市属医疗机构也分别和保定市5家医疗机构同时签订了医疗合作协议,以快速提升保定市医疗

京津冀建医学影音中心

今天,“京东京津冀医疗协同发展大会”在北京平谷举行。会上,北京市平谷区卫生计生委与天津市蓟州区,河北省秦皇岛市、承德市、唐山市、廊坊市卫生计生委分别签订《京东京津冀医疗协同发展合作协议》。

利好:一张片子三地通用,京津冀共享医学影像资料

以往跨地区、跨医院就诊时,碰到重复的X光、CT检验项目,由于检验结果难以互认,患者只能重新检查。12月26日,京津冀医疗机构医学影像检查资料共享工作启动会举行。会议指出,京津冀三地卫生计生委决定,自2017年1月1日起正式实施三地医疗机构医学影像检查资料共享试点工作。这意味着,符合条件的患者,在102家试点医院内做的17项共享检查,将无需重复检查。据介绍,京津冀医疗机构医学影像检查资料共享,是指患

京冀医疗合作 河北患者降至7.5%

京津冀三地已陆续签订医政、疾病防控、采供血等多方面合作协议,多个京冀重点项目扎实推进。河北患者人数占比从2013年的9.1%降至2016年7.5%,京冀医疗协同发展成效初显。

京津冀设“医疗服务带”签署六大医疗合作项目

京津冀签署六项合作计划,其中张家口、承德、廊坊等河北多地将与北京开展医疗合作。目前安排及正在安排的疏解大型医院达到20余家。

霾黄色预警继续 京津冀等部分地区有重度霾

  图片来源:中央气象台 据中央气象台消息,中央气象台今日6时继续发布霾黄色预警,北京、天津、河北、山东、河南、陕西、山西等地大部地区有中度霾,其中京津冀等地部分地区有重度霾。 中央气象台2月24日06时继续发布霾黄色预警:预计24日08时至25日08时,北京、天津、河北、山东西部、河南中北部、陕西关中地区、山西东部等地气象条件不利于空气中污染物扩散,大部地区有中度霾,